In the latest session, Bionomics Ltd. ADR (NASDAQ: BNOX) closed at $1.00 down -3.98% from its previous closing price of $1.04. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 2062698 shares were traded.
Ratios:
For a deeper understanding of Bionomics Ltd. ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.87 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 28, 2023, Maxim Group reiterated its Buy rating and also lowered its target price recommendation from $7 to $10.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $54.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $54 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNOX now has a Market Capitalization of 10.69M and an Enterprise Value of -868.17k. For the stock, the TTM Price-to-Sale (P/S) ratio is 1069.00 while its Price-to-Book (P/B) ratio in mrq is 0.54. Its current Enterprise Value per Revenue stands at -39.38 whereas that against EBITDA is 0.03.
Stock Price History:
Over the past 52 weeks, BNOX has reached a high of $6.41, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 1.0828, while the 200-Day Moving Average is calculated to be 1.8351.
Shares Statistics:
For the past three months, BNOX has traded an average of 221.79K shares per day and 270.26k over the past ten days. A total of 8.16M shares are outstanding, with a floating share count of 8.15M. Shares short for BNOX as of Feb 29, 2024 were 86.21k with a Short Ratio of 0.39, compared to 252.28k on Jan 31, 2024.
Earnings Estimates
There are 0 different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $15k in the next fiscal year. The high estimate is $5.54M and the low estimate is $940k. The average revenue growth estimate for next year is down -91.80% from the average revenue estimate for this year.
